New stock news | Shenzhen Salubris Pharmaceuticals (002294.SZ) plans to list on the Hong Kong Stock Exchange. The China Securities Regulatory Commission requires clarification on the proportion of fundraising for domestic and overseas purposes.

On April 3, the China Securities Regulatory Commission announced the supplementary materials requirements for overseas issuance and listing disclosure (March 30, 2026 - April 3, 2026). The CSRC required Shenzhen Salubris Pharmaceuticals (002294.SZ) to provide additional explanations on the domestic and foreign use ratio of the raised funds, whether there are plans to repatriate funds domestically and the specific ratio for repatriation, whether they are involved in overseas investment projects, and whether they have obtained necessary approvals from relevant regulatory authorities. According to the disclosure by the Hong Kong Stock Exchange on February 12, Shenzhen Salubris Pharmaceuticals submitted a listing application to the HKEX, with Goldman Sachs, Citigroup, and CITIC SEC as its joint sponsors. At the same time, the CSRC required Shenzhen Salubris Pharmaceuticals to explain the establishment and changes in shareholders of the limited liability company during the given period in accordance with the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing No. 2." They also needed to provide detailed information on the regulatory procedures for establishing overseas subsidiaries, overseas investments, and foreign exchange registration, and issue a conclusion on compliance. According to the prospectus, the company is a pioneer in the field of cardiovascular-kidney-metabolic (cardiorenal-metabolic syndrome) disease treatment in China. According to data from Frost & Sullivan, in 2024, the company was the second largest pharmaceutical company in China in terms of revenue in the cardiovascular innovative drug field. As of the last practicable date (February 4, 2026), according to Frost & Sullivan data, the company has the second largest cardiorenal-metabolic syndrome innovative drug pipeline among domestic companies in terms of scale. As of the last practicable date, the company has six innovative drugs - Xintan (approved in 2013), Fulitan (approved in 2024), Xinting (approved in 2024), Xinchuotuo (approved in 2025), Fulian (approved in 2025), and Enlaro (initially approved in 2023, with expanded indications approved in 2025).